Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Background: Two main approaches are employed to monitor healthcare-associated infections (HAIs): longitudinal surveillance, which allows the measurement of incidence rates, and point prevalence surveys (PPSs). PPSs are less time-consuming; however, they are affected by length-biased sampling, which can be corrected through inverse probability weighting. We assessed the accuracy of this method by analysing data from two Italian national surveillance systems.
Methods: Ventilator-associated pneumonia (VAP) and central-line-associated bloodstream infection (CLABSI) incidence measured through a prospective surveillance system (GiViTI) was compared with incidence estimates obtained through conversion of crude and inverse probability weighted prevalence of the same HAIs in intensive care units (ICUs) measured through a PPS. Weighted prevalence rates were obtained after weighting all patients inversely proportional to their time-at-risk. Prevalence rates were converted into incidence per 100 admissions using an adapted version of the Rhame and Sudderth formula.
Findings: Overall, 30,988 patients monitored through GiViTI, and 1435 patients monitored through the PPS were included. A significant difference was found between incidence rates estimated based on crude VAP and CLABSI prevalence and measured through GiViTI (relative risk 2.5 and 3.36; 95% confidence interval 1.42-4.39 and 1.33-8.53, P=0.006 and 0.05, respectively). Conversely, no significant difference was found between incidence rates estimated based on weighted VAP and CLABSI prevalence and measured through GiViTI (P=0.927 and 0.503, respectively).
Conclusions: When prospective surveillance is not feasible, our simple method could be useful to obtain more accurate incidence rates from PPS data.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jhin.2024.10.009 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!